KRAS and non-small cell lung carcinoma: Emerging evidence suggests that KRAS mutations may modulate PD-L1 expression and influence immunotherapy responses, underscoring the need for prospective studies integrating comprehensive genomic profiling in elderly NSCLC cohorts[47].